Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma.
Srivandana AkshintalaR Taylor SundbyDonna B BernsteinJohn W GlodRosandra N KaplanMarielle E YoheAndrea M GrossJoanne DerdakHaiyan LeiAlexander PanEva DombiIsabel Palacio-YanceKailey R HerreraMarkku M MiettinenHelen X ChenSeth M SteinbergLee J HelmanLeo MascarenhasBrigitte C WidemannFariba NavidJack F ShernChristine M HeskePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
The combination of dasatinib 60 mg/m2/dose daily and ganitumab 18 mg/kg every two weeks was safe and tolerable. This combination had a disease control rate of 22% at five months.